Birchview Capital’s Travere Therapeutics TVTX Stock Holding History

Birchview Capital’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.65M	Sell	29,000 -200	-0.7%	-$8.87K	0.77%	32
2026 Q1	$868K	Sell	29,200 -13,800	-32%	-$413K	0.49%	44
2025 Q4	$1.64M	Sell	43,000 -60	-0.1%	-$1.95K	0.96%	29
2025 Q3	$1.03M	Sell	43,060 -59,940	-58%	-$1.13M	0.78%	37
2025 Q2	$1.52M	Sell	103,000 -35,000	-25%	-$580K	1.51%	19
2025 Q1	$2.47M	Sell	138,000 -10,000	-7%	-$203K	2.15%	10
2024 Q4	$2.58M	Hold	148,000	–	–	2.1%	13
2024 Q3	$2.07M	Buy	148,000 +26,000	+21%	+$271K	1.79%	16
2024 Q2	$1M	Hold	122,000	–	–	0.93%	22
2024 Q1	$941K	Hold	122,000	–	–	0.77%	27
2023 Q4	$1.1M	Buy	122,000 +40,000	+49%	+$291K	0.86%	26
2023 Q3	$733K	Buy	82,000 +42,000	+105%	+$593K	0.62%	28
2023 Q2	$614K	Buy	40,000 +10,000	+33%	+$182K	0.46%	33
2023 Q1	$675K	Buy	+30,000	New	+$638K	0.53%	27

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Birchview Capital's TVTX Position: Q2 2026 in Review

Birchview Capital reduced its Travere Therapeutics (TVTX) stake by 0.68% in Q2 2026, selling an estimated $8.87K and leaving 29,000 shares worth $1.65M. The position accounts for 0.77% of the portfolio, ranked #32.

Birchview Capital first reported a position in TVTX in Q1 2023 and has held it in 14 quarters since. The position peaked at $2.58M in Q4 2024. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Birchview Capital held 29,000 shares of Travere Therapeutics worth $1.65M as of Q2 2026.
Birchview Capital sold 200 Travere Therapeutics shares in Q2 2026, an estimated $8.87K.
Travere Therapeutics made up 0.77% of Birchview Capital's portfolio in Q2 2026, its #32 holding.
Birchview Capital first reported a position in Travere Therapeutics in Q1 2023 and has held it in 14 quarters since.
Birchview Capital's Travere Therapeutics position peaked at $2.58M in Q4 2024.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.